What does this research mean for the field?

Ocrelizumab provides clinical benefit and demonstrates a manageable safety profile in real-world patients with advanced progressive multiple sclerosis in a developing nation. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To describe real-world effectiveness, tolerability, and safety outcomes of ocrelizumab in adult patients with progressive multiple sclerosis treated at a tertiary center in Libya.

August 23, 2026Ibnosina Journal of Medicine and Biomedical SciencesOpen Access

Ocrelizumab Use in Patients with Progressive Multiple Sclerosis: A Single Center Experience from a Developing Nation

View Full Paper

Ask AI

Bookmark

Authors

ABAnwaar BennourUniversity of Benghazi HEHeba Abdel-Razek El-ZawawiUniversity of Benghazi

Discussion

Member takes

Implication

Retrospective cohort study reveals disability stabilization and improvement with ocrelizumab in progressive multiple sclerosis, suggesting clinical utility in advanced disease.

Key Points

To describe real-world effectiveness, tolerability, and safety outcomes of ocrelizumab in adult patients with progressive multiple sclerosis treated at a tertiary center in Libya.
Retrospective, single-center observational study conducted in Benghazi, Libya, enrolling 25 adult patients (median age 41 years; 60% male; 96% secondary progressive MS, 4% primary progressive MS).
Patients received standard ocrelizumab infusions between May 2022 and May 2023 with a median follow-up of 12 months (range: 8–24 months).
Disability progression was assessed using the Expanded Disability Status Scale (EDSS) from baseline to final follow-up.
Following treatment, 44% (11/25) of patients demonstrated clinical stability, 32% (8/25) showed disability improvement, and 20% (5/25) experienced disability progression.
One patient (4%) discontinued therapy due to pregnancy.
Infusion-related reactions occurred in 36% (9/25) of patients, while serious adverse events included one cardiac death (4%) and one case of bilateral breast cancer (4%).

Cite This Study

Bennour et al. (2026) studied this question.

synapsesocial.com/papers/6a8aadf37677a341144467a8 https://doi.org/10.1055/s-0046-1827482

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reveals disability stabilization and improvement with ocrelizumab in progressive multiple sclerosis, suggesting clinical utility in advanced disease.

Ocrelizumab Use in Patients with Progressive Multiple Sclerosis: A Single Center Experience from a Developing Nation

Discussion

Member takes

Implication

Key Points

Cite This Study

Ocrelizumab Use in Patients with Progressive Multiple Sclerosis: A Single Center Experience from a Developing Nation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider